<bill session="115" type="s" number="2157" updated="2023-01-11T13:39:21Z">
  <state datetime="2017-11-16">REFERRED</state>
  <status>
    <introduced datetime="2017-11-16"/>
  </status>
  <introduced datetime="2017-11-16"/>
  <titles>
    <title type="display">Drug-Price Transparency in Communications Act</title>
    <title type="short" as="introduced">Drug-Price Transparency in Communications Act</title>
    <title type="official" as="introduced">A bill to require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.</title>
  </titles>
  <sponsor bioguide_id="D000563"/>
  <cosponsors>
    <cosponsor bioguide_id="B001277" joined="2018-06-20"/>
    <cosponsor bioguide_id="B000944" joined="2017-11-16"/>
    <cosponsor bioguide_id="F000457" joined="2017-11-16"/>
    <cosponsor bioguide_id="G000555" joined="2017-12-14"/>
    <cosponsor bioguide_id="H001075" joined="2017-11-16"/>
    <cosponsor bioguide_id="H001076" joined="2017-11-16"/>
    <cosponsor bioguide_id="K000383" joined="2017-11-16"/>
  </cosponsors>
  <actions>
    <action datetime="2017-11-16">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2017-11-16" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="115" type="h" number="6576" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-29T21:20:06Z" status="Introduced in Senate">Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.</summary>
</bill>
